Arthritis News and Research

Latest Arthritis News and Research

LTW Technologies' LED LIGHTWAVE therapy device receives 5 FDA clearances

LTW Technologies has received 5 FDA clearances (K082586) for its proprietary and unique multi-wavelength LED LIGHTWAVE therapy device. The LIGHTWAVE DELUXE series utilizes a revolutionary light therapy combination of Red light therapy, Blue light therapy and Infrared light therapy.

25 Jan 2010

Biogen Idec and Swedish Orphan Biovitrum commence dosing in rFIXFc Phase I/IIa trial for hemophilia B

Biogen Idec and Swedish Orphan Biovitrum today announced that the first patient was dosed in a registrational, open-label, multicenter trial designed to evaluate the safety, pharmacokinetics and efficacy of the companies’ long-acting, recombinant Factor IX Fc fusion protein (rFIXFc) in hemophilia B patients.

25 Jan 2010

Loss of key proteins may account for molecular abnormalities associated with myotonic dystrophy

Research on the genetic defect that causes myotonic muscular dystrophy has revealed that the mutation disrupts an array of metabolic pathways in muscle cells through its effects on two key proteins.

24 Jan 2010

Biogen Idec's statement on FDA approval of AMPYRA

Biogen Idec today issued the following statement regarding the United States (U.S.) Food and Drug Administration (FDA) approval of AMPYRA™ (dalfampridine) to improve walking in patients with multiple sclerosis (MS).

23 Jan 2010

MACI/ACI therapies could prevent total joint replacement in OA patients

Osteoarthritis (OA) is one of the ten most disabling diseases in the developed world and is set to become more of a financial burden on health services as average life expectancy increases.

23 Jan 2010

Mice study shows obesity can increase risk of developing liver cancer

Obesity comes with plenty of health risks, but there's one that's perhaps not so well known: an increased risk of developing cancer, and especially certain types of cancer like liver cancer. Now, a group of researchers reporting in the January 22nd issue of the journal Cell, a Cell Press publication, have confirmed in mice that obesity does indeed act as a "bona fide tumor promoter." They also have good evidence to explain how that happens.

22 Jan 2010

Scientific/technical review for XIAFLEX' European MAA commences

BioSpecifics Technologies Corp., a biopharmaceutical company developing first in class collagenase-based products, today announced that its partner Auxilium Pharmaceuticals, Inc. announced that Pfizer Inc. received notification from the European Medicines Agency that the Marketing and Authorization Application (MAA) for XIAFLEX™ for the treatment of Dupuytren's disease (a debilitating disorder resulting from excessive collagen deposition that causes contractures of the fingers) has completed the validation phase successfully and that the scientific/technical review procedure commenced today.

21 Jan 2010

Amgen announces results of two Phase 3 studies evaluating Vectibix for mCRC

Amgen today announced that detailed results from two pivotal Phase 3 studies evaluating Vectibix® (panitumumab) in combination with chemotherapy for the first and second-line treatment of metastatic colorectal cancer (mCRC) (the PRIME '203' and '181' trials, respectively) will be presented at the 2010 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium in Orlando, Florida from Jan. 22-24, 2010.

21 Jan 2010

Abaxis' new CRP assay receives FDA marketing clearance

Abaxis, Inc., a medical products company manufacturing point-of-care blood analysis systems, today announced that the U.S. Food and Drug Administration (FDA) has granted 510K marketing clearance of the new C-Reactive Protein (CRP) assay when used by healthcare professionals in conjunction with the Piccolo Xpress™ point-of-care analyzer.

21 Jan 2010

Dosing in First-in-Man Phase I study of 4SC AG's 4SC-203 commenced

4SC AG, a drug discovery and development company, today announced the start of dosing in a First-in-Man Phase I study in healthy volunteers evaluating 4SC-203, a novel multi-target kinase inhibitor, with particular specificity against selected kinases, including FMS-like tyrosine kinase 3 (FLT3), FLT3 mutants and vascular endothelial growth factor receptors (VEGF-R).

21 Jan 2010

Research shows brain abnormalities develop years before Parkinson's symptoms appear

Scientists who have identified brain networks damaged in Parkinson's disease have new evidence that these systems become abnormal a few years before symptoms appear. And what's more, parts of the network appear to respond in a last ditch attempt to rescue the brain.

21 Jan 2010

VisEn Medical announces the commercial launch of new Cat B 680 FAST imaging agent

VisEn Medical Inc., a leader in fluorescence in vivo imaging from research through medicine, announced today the commercial launch of its new Cat B 680 FAST™ imaging agent for measuring and monitoring cathepsin B activity associated with disease progression and therapeutic response in vivo.

21 Jan 2010

New study may help develop assessment tests in social-emotional learning

Neurobehavioral researchers at Rush University Medical Center have found three key factors in a child's behavior that can lead to social rejection. The studies are a crucial step in developing scientifically sound screening tests and treatment planning for social-emotional learning difficulties.

20 Jan 2010

Lexicon Pharmaceuticals reports positive results from its LX4211 Phase 2 trial in type 2 diabetic patients

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering breakthrough treatments for human disease, obtained positive results from a recently completed Phase 2 study of LX4211 in patients with type 2 diabetes mellitus. LX4211 is a once-per-day, orally-delivered, small molecule drug candidate that inhibits the sodium-dependent glucose transporter 2 (SGLT2), lowering the accumulation of glucose in the body and reducing caloric load.

20 Jan 2010

$SIR supports use of vertebral augmentation for patients with spine fractures$

SIR supports use of vertebral augmentation for patients with spine fractures

Given the current controversy over vertebroplasty-a minimally invasive treatment performed by interventional radiologists in individuals with painful osteoporotic vertebral compression fractures that fail to respond to conventional medical therapy-what's a patient to do?

20 Jan 2010

QuantRx Biomedical's developments in genetics-based technology

QuantRx® Biomedical Corporation, a broad-based diagnostic company focused on the development and commercialization of innovative diagnostic products, today provided an update from Chairman and Chief Executive Officer Walter Witoshkin on its involvement in genetics-based personalized medicine and disease prevention.

20 Jan 2010

Use of braces in adolescent idiopathic scoliosis is still an area of controversy

The use of braces to correct excessive curvature of the spine, or scoliosis, in adolescents is still an area of controversy — and is likely to remain that way until there is better evidence, concludes a new review of published research. Although some evidence points toward a benefit from using braces, research has failed to prove definitively that they work.

20 Jan 2010

Perseid Therapeutics to co-develop and commercialize next-generation CTLA4-Ig therapeutics

Maxygen, Inc., a biotechnology company focused on the development of improved protein drugs, today announced that its majority-owned subsidiary, Perseid Therapeutics LLC, achieved a preclinical milestone under its collaboration with Astellas Pharma Inc. to co-develop and commercialize next-generation CTLA4-Ig therapeutics.

19 Jan 2010

New type of fat-producing cells may speed up treatments for muscular dystrophy and fibrosis

A team of University of British Columbia researchers has identified fat-producing cells that possess "dual-personalities" and may further the development of treatments for muscle diseases such as muscular dystrophy and fibrosis.

19 Jan 2010

Study examines how opioid overdose differs by prescribed dose for chronic pain conditions

More and more Americans with chronic pain not caused by cancer are taking medically prescribed opioids like Oxycontin (oxycodone) and Vicodin (hydrocodone). The January 19 Annals of Internal Medicine features the first study to explore the risk of overdose in patients prescribed opioids for chronic noncancer pain in general health care.

19 Jan 2010

Arthritis News and Research

Latest Arthritis News and Research

LTW Technologies' LED LIGHTWAVE therapy device receives 5 FDA clearances

Biogen Idec and Swedish Orphan Biovitrum commence dosing in rFIXFc Phase I/IIa trial for hemophilia B

Loss of key proteins may account for molecular abnormalities associated with myotonic dystrophy

Biogen Idec's statement on FDA approval of AMPYRA

MACI/ACI therapies could prevent total joint replacement in OA patients

Mice study shows obesity can increase risk of developing liver cancer

Scientific/technical review for XIAFLEX' European MAA commences

Amgen announces results of two Phase 3 studies evaluating Vectibix for mCRC

Abaxis' new CRP assay receives FDA marketing clearance

Dosing in First-in-Man Phase I study of 4SC AG's 4SC-203 commenced

Research shows brain abnormalities develop years before Parkinson's symptoms appear

VisEn Medical announces the commercial launch of new Cat B 680 FAST imaging agent

New study may help develop assessment tests in social-emotional learning

Lexicon Pharmaceuticals reports positive results from its LX4211 Phase 2 trial in type 2 diabetic patients

SIR supports use of vertebral augmentation for patients with spine fractures

QuantRx Biomedical's developments in genetics-based technology

Use of braces in adolescent idiopathic scoliosis is still an area of controversy

Perseid Therapeutics to co-develop and commercialize next-generation CTLA4-Ig therapeutics

New type of fat-producing cells may speed up treatments for muscular dystrophy and fibrosis

Study examines how opioid overdose differs by prescribed dose for chronic pain conditions

Transforming Cardiovascular Care: Insights from Mina Makar at AstraZeneca

Clue's CEO Rhiannon White on the Future of Femtech and PCOS

Freezing Point Osmometry in Life Science Applications

Arthritis News and Research

Latest Arthritis News and Research

Transforming Cardiovascular Care: Insights from Mina Makar at AstraZeneca

Clue's CEO Rhiannon White on the Future of Femtech and PCOS

Freezing Point Osmometry in Life Science Applications

Newsletters you may be interested in